ha ha, that would be nice, I'd be good to retire then.
@bedger - thanks for chipping in. They said 8% of Q1 22 revenue was accountable to EU. Noting the choice of words, I think EU still contributes a very small part towards revenue, I don't see why they would not have addressed it towards the Q3 22 figures otherwise.
So at this stage I would personally not presume EU sales would fill that gap. Q2, 3 and 4 figures would be crucial for us (noting no other SP driving news is forecasted this year from what is known).
**@bedger: Btw I see your posts on OrthoCell, very interesting company. Researching OrthoCell and Aroa Biosurgery Ltd currently (for my portfolio).
Ann: Activities Update Qtr Ending March 2023 and Appendix 4C, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $1.830M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $1.446K | 135.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1417447 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 265451 | 3 |
View Market Depth
| Last trade - 11.49am 25/06/2025 (20 minute delay) ? |
| OSX (ASX) Chart |